Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

NCT06818292 · Completed

Last updated 2026-05-28

This clinical trial examines how GLP-1 agonists affect brain and body metabolism in healthy individuals, focusing on changes in thinking speed.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind basic-science study

Participants 10 people

Who can join Ages 18–43 · all sexes Healthy volunteers accepted.

Timeline Started 2024-10 · est. completion 2024-12

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06818292 ↗

Description as written by the study sponsor.

This study aims to investigate the acute effects of Liraglutide, a GLP-1 receptor agonist established in the treatment of type 2 diabetes and obesity, on brain metabolism, brain network function, and executive functioning as well as mood in healthy, normal-weight individuals. Given the emerging evidence of GLP-1's impact on brain function, including the modulation of reward processing and cognitive functions, this study will focus on the physiological changes induced by Liraglutide and their potential implications for brain health. The overall goal of this study is to assess how acute GLP-1 administration influences systemic and brain metabolism to modulate brain signalling and behaviour.

Treatments tested

Liraglutide also known as GLP-1 Agonist Biologic

0.6 mg of the pre-filled solutions from pen-injector Liraglutide (GLP-1 Agonist)
Placebo Biologic

0.1 mL NaCl

Main thing measured	Neuropsychology: Processing speed
Sponsor	Nils Opel
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06818292 ↗